Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial

B. Massie, M. Bourassa, R. DiBianco, M. Hess, M. Konstam, M. Likoff, M. Packer

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure. The present multicenter trial was designed to prospectively evaluate clinical response and change in exercise tolerance during 12 weeks of amrinone therapy in a double-blind, placebo-controlled protocol. Ninety-nine patients with NYHA functional class 3 or 4 congestive heart failure on digitalis and diuretics, of whom 31 were also receiving captopril, were enrolled. After baseline clinical assessment and determination of exercise tolerance, radionuclide left ventricular ejection fraction, and roentgenographic cardiothoracic ratio, patients were randomly assigned to receive amrinone or placebo, beginning at 1.5 mg/kg tid and increasing to a maximum dosage of 200 mg tid. After 12 weeks of therapy or at the last blinded evaluation in patients who did not complete this protocol, there were no significant differences from baseline values between treatment with amrinone or placebo with regard to symptoms, NYHA functional class, left ventricular ejection fraction, cardiothoracic ratio, frequency and severity of ventricular ectopy, or mortality. Exercise tolerance improved significantly from baseline by 37 ± 10% (mean 163 sec) in patients on amrinone and 35 ± 11% (mean 149 sec) in patients on placebo, but there was no significant difference between treatments. Adverse reactions were significantly more frequent and more severe on amrinone, occurring in 83% of patients and necessitating withdrawal in 34%. Downward adjustment of amrinone dosage because of side effects was responsible for a significantly lower mean total daily dose of 355 vs 505 mg for placebo (P < .001). These findings indicate that oral administration of amrinone is not clinically effective in patients with chronic congestive heart failure, in part because of frequent adverse effects.

Original languageEnglish (US)
Pages (from-to)963-971
Number of pages9
JournalCirculation
Volume71
Issue number5
StatePublished - 1985

Fingerprint

Amrinone
Multicenter Studies
Oral Administration
Heart Failure
Placebos
Exercise Tolerance
Stroke Volume
Phosphodiesterase Inhibitors
Digitalis
Captopril
Therapeutics
Diuretics
Radioisotopes

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Massie, B., Bourassa, M., DiBianco, R., Hess, M., Konstam, M., Likoff, M., & Packer, M. (1985). Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation, 71(5), 963-971.

Long-term oral administration of amrinone for congestive heart failure : Lack of efficacy in a multicenter controlled trial. / Massie, B.; Bourassa, M.; DiBianco, R.; Hess, M.; Konstam, M.; Likoff, M.; Packer, M.

In: Circulation, Vol. 71, No. 5, 1985, p. 963-971.

Research output: Contribution to journalArticle

Massie, B, Bourassa, M, DiBianco, R, Hess, M, Konstam, M, Likoff, M & Packer, M 1985, 'Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial', Circulation, vol. 71, no. 5, pp. 963-971.
Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M et al. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation. 1985;71(5):963-971.
Massie, B. ; Bourassa, M. ; DiBianco, R. ; Hess, M. ; Konstam, M. ; Likoff, M. ; Packer, M. / Long-term oral administration of amrinone for congestive heart failure : Lack of efficacy in a multicenter controlled trial. In: Circulation. 1985 ; Vol. 71, No. 5. pp. 963-971.
@article{274bef76a87c413fb7ba068330f56eb7,
title = "Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial",
abstract = "A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure. The present multicenter trial was designed to prospectively evaluate clinical response and change in exercise tolerance during 12 weeks of amrinone therapy in a double-blind, placebo-controlled protocol. Ninety-nine patients with NYHA functional class 3 or 4 congestive heart failure on digitalis and diuretics, of whom 31 were also receiving captopril, were enrolled. After baseline clinical assessment and determination of exercise tolerance, radionuclide left ventricular ejection fraction, and roentgenographic cardiothoracic ratio, patients were randomly assigned to receive amrinone or placebo, beginning at 1.5 mg/kg tid and increasing to a maximum dosage of 200 mg tid. After 12 weeks of therapy or at the last blinded evaluation in patients who did not complete this protocol, there were no significant differences from baseline values between treatment with amrinone or placebo with regard to symptoms, NYHA functional class, left ventricular ejection fraction, cardiothoracic ratio, frequency and severity of ventricular ectopy, or mortality. Exercise tolerance improved significantly from baseline by 37 ± 10{\%} (mean 163 sec) in patients on amrinone and 35 ± 11{\%} (mean 149 sec) in patients on placebo, but there was no significant difference between treatments. Adverse reactions were significantly more frequent and more severe on amrinone, occurring in 83{\%} of patients and necessitating withdrawal in 34{\%}. Downward adjustment of amrinone dosage because of side effects was responsible for a significantly lower mean total daily dose of 355 vs 505 mg for placebo (P < .001). These findings indicate that oral administration of amrinone is not clinically effective in patients with chronic congestive heart failure, in part because of frequent adverse effects.",
author = "B. Massie and M. Bourassa and R. DiBianco and M. Hess and M. Konstam and M. Likoff and M. Packer",
year = "1985",
language = "English (US)",
volume = "71",
pages = "963--971",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Long-term oral administration of amrinone for congestive heart failure

T2 - Lack of efficacy in a multicenter controlled trial

AU - Massie, B.

AU - Bourassa, M.

AU - DiBianco, R.

AU - Hess, M.

AU - Konstam, M.

AU - Likoff, M.

AU - Packer, M.

PY - 1985

Y1 - 1985

N2 - A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure. The present multicenter trial was designed to prospectively evaluate clinical response and change in exercise tolerance during 12 weeks of amrinone therapy in a double-blind, placebo-controlled protocol. Ninety-nine patients with NYHA functional class 3 or 4 congestive heart failure on digitalis and diuretics, of whom 31 were also receiving captopril, were enrolled. After baseline clinical assessment and determination of exercise tolerance, radionuclide left ventricular ejection fraction, and roentgenographic cardiothoracic ratio, patients were randomly assigned to receive amrinone or placebo, beginning at 1.5 mg/kg tid and increasing to a maximum dosage of 200 mg tid. After 12 weeks of therapy or at the last blinded evaluation in patients who did not complete this protocol, there were no significant differences from baseline values between treatment with amrinone or placebo with regard to symptoms, NYHA functional class, left ventricular ejection fraction, cardiothoracic ratio, frequency and severity of ventricular ectopy, or mortality. Exercise tolerance improved significantly from baseline by 37 ± 10% (mean 163 sec) in patients on amrinone and 35 ± 11% (mean 149 sec) in patients on placebo, but there was no significant difference between treatments. Adverse reactions were significantly more frequent and more severe on amrinone, occurring in 83% of patients and necessitating withdrawal in 34%. Downward adjustment of amrinone dosage because of side effects was responsible for a significantly lower mean total daily dose of 355 vs 505 mg for placebo (P < .001). These findings indicate that oral administration of amrinone is not clinically effective in patients with chronic congestive heart failure, in part because of frequent adverse effects.

AB - A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure. The present multicenter trial was designed to prospectively evaluate clinical response and change in exercise tolerance during 12 weeks of amrinone therapy in a double-blind, placebo-controlled protocol. Ninety-nine patients with NYHA functional class 3 or 4 congestive heart failure on digitalis and diuretics, of whom 31 were also receiving captopril, were enrolled. After baseline clinical assessment and determination of exercise tolerance, radionuclide left ventricular ejection fraction, and roentgenographic cardiothoracic ratio, patients were randomly assigned to receive amrinone or placebo, beginning at 1.5 mg/kg tid and increasing to a maximum dosage of 200 mg tid. After 12 weeks of therapy or at the last blinded evaluation in patients who did not complete this protocol, there were no significant differences from baseline values between treatment with amrinone or placebo with regard to symptoms, NYHA functional class, left ventricular ejection fraction, cardiothoracic ratio, frequency and severity of ventricular ectopy, or mortality. Exercise tolerance improved significantly from baseline by 37 ± 10% (mean 163 sec) in patients on amrinone and 35 ± 11% (mean 149 sec) in patients on placebo, but there was no significant difference between treatments. Adverse reactions were significantly more frequent and more severe on amrinone, occurring in 83% of patients and necessitating withdrawal in 34%. Downward adjustment of amrinone dosage because of side effects was responsible for a significantly lower mean total daily dose of 355 vs 505 mg for placebo (P < .001). These findings indicate that oral administration of amrinone is not clinically effective in patients with chronic congestive heart failure, in part because of frequent adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0021865534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021865534&partnerID=8YFLogxK

M3 - Article

C2 - 3886191

AN - SCOPUS:0021865534

VL - 71

SP - 963

EP - 971

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -